Diethylstilbestrol and adenocarcinoma of the vagina

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 6, 1999, Pages 1576-1578

  Herbst, Arthur L ^a  

^a THE UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL;

CANCER INCIDENCE; CARCINOGENICITY; CLEAR CELL CARCINOMA; FEMALE; HUMAN; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; VAGINA ADENOSIS; VAGINA CARCINOMA;

EID: 0033397855     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70412-6     Document Type: Article

References (17)

1. 1. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolesrence: a report of 7 cases including 6 clear cell carcinomas (so-called mesonephromas). Cancer 1970;25:745-57.
2. 2. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.
3. 3. Greenwald P, Barlow JJ, Nasca PC, Burnett WS. Vaginal cancer after maternal treatment with synthetic estrogens. N Engl J Med 1971;284:390-2.
4. 4. Smith OW, Smith GVS, Hurwitz D. Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents. Am J Obstet Gynecol 1946;51:411-5.
5. 5. Herbst AL, Kurman RJ, Scully RE. Vaginal and cervical abnormalities following exposure to stilbestrol in utero. Obstet Gynecol 1972;40:287-98.
6. 6. Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE. Prenatal exposure to stilbestrol: a prospective comparison of exposed female offspring with unexposed controls. N Engl J Med 1975;292:334-9.
7. 7. Herbst AL, Kurman RJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the genital tract in young females: Registry report. N Engl J Med 1972;287:1259-64.
8. 8. Herbst AL, Cole P, Norusis MJ, Welch WR, Scully RE. Epidemiologic aspects and factors related to survival in 384 cases of dear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 1979;135:876-86.
9. 9. Melnick S, Cole P, Anderson D, Herbst AL. Rates and risks of diethylstilbestrol related to clear cell adenocarcinoma of the vagina and cervix. N Engl J Med 1987;316:514-6.
10. 10. Dieckmann WJ, Davis ME, Rynkiewicz SM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol 1953;66:1062-81.
11. 11. Herbst AL, Hubby MM, Blough RR, et al. A comparison of pregnancy experience in DES-exposed and DES-unexposed daughters. J Reprod Med 1980;24:62-9.
12. 12. Herbst AL, Bern HA. Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme-Stratton; 1981.
13. 13. Cunha GR, Fujii H. Stromal-parenchymal interactions in normal and abnormal development of the genital tract. In: Herbst AL, Bern HA, editors. Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme-Stratton; 1981. p. 179-93.
14. 14. Waggoner SE, Mittendorf RL, Biney N, Anderson D, Herbst AL. Influence of in utero diethylstilbestrol exposure on the prognosis and biologic behavior of vaginal clear cell adenocarcinoma. Gynecol Oncol 1994;55:238-44.
15. 15. Collins J, Donner A, Allen LH, Adams O. Oestrogen use and survival in endometrial cancer. Lancet 1980;2:961-4.
16. 16. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 of 297 women with breast cancer and 100 of 239 women without breast cancer from 54 epidemiologic studies. Lancet 1996;347:1713-27.
17. 17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.